Department of Social and Preventive Medicine, 1050 ave de la Médecine, Université Laval, Québec G1V 0A6, Canada; Institut national de santé publique du Québec, 945 ave Wolfe, Québec G1V 5B3, Canada.
Department of Social and Preventive Medicine, 1050 ave de la Médecine, Université Laval, Québec G1V 0A6, Canada; Institut national de santé publique du Québec, 945 ave Wolfe, Québec G1V 5B3, Canada; Centre d'Excellence sur le Vieillissement de Québec, 1050 Chemin Ste-Foy, Local L2-28, Québec G1S 4L8, Canada.
Prim Care Diabetes. 2020 Oct;14(5):529-537. doi: 10.1016/j.pcd.2020.03.003. Epub 2020 May 10.
To study the population-based prevalence of potentially inappropriate medication (PIM) among older individuals with diabetes, and to identify factors associated with their use.
We used the Quebec Integrated Chronic Disease Surveillance System (QICDSS) database to conduct a population-based cohort study of individuals with diabetes ≥66 years between April 1st, 2014 and March 31st, 2015. PIMs were defined according to the 2015 Beers Criteria. Factors associated with PIM use were identified using robust Poisson regression models. Risk ratios (RR) and 99% confidence intervals (99%CI) were calculated.
More than half (56%) of the 286,962 older individuals with diabetes used at least one PIM over a year. Benzodiazepines (41%), proton pump inhibitors (27%) and endocrine medication (mainly glibenclamide) (25%) were the most common PIMs used. Factors associated with PIM use included female sex (RR: 1.17; 99%CI: 1.16-1.18), and comorbidities such as schizophrenia (1.48; 1.45-1.51), anxiety disorders (1.34; 1.33-1.35) and Alzheimer's disease (1.14; 1.13-1.25). Risks of using PIMs increased both with increasing comorbidities and number of medications.
PIM use is highly prevalent among older individuals with diabetes. Interventions to promote optimal medication use should particularly target individuals with comorbidities and polypharmacy who are most vulnerable to adverse drug events.
研究基于人群的糖尿病老年患者潜在不适当药物(PIM)的流行情况,并确定与 PIM 使用相关的因素。
我们使用魁北克综合慢性病监测系统(QICDSS)数据库,对 2014 年 4 月 1 日至 2015 年 3 月 31 日期间≥66 岁的糖尿病患者进行了基于人群的队列研究。根据 2015 年 Beers 标准定义 PIM。使用稳健泊松回归模型确定与 PIM 使用相关的因素。计算风险比(RR)和 99%置信区间(99%CI)。
超过一半(56%)的 286962 名老年糖尿病患者在一年内至少使用了一种 PIM。最常用的 PIM 是苯二氮䓬类(41%)、质子泵抑制剂(27%)和内分泌药物(主要是格列本脲)(25%)。与 PIM 使用相关的因素包括女性(RR:1.17;99%CI:1.16-1.18),以及合并症,如精神分裂症(1.48;1.45-1.51)、焦虑症(1.34;1.33-1.35)和阿尔茨海默病(1.14;1.13-1.25)。随着合并症和用药数量的增加,使用 PIM 的风险也随之增加。
糖尿病老年患者中 PIM 的使用非常普遍。促进最佳药物使用的干预措施应特别针对最容易发生药物不良反应的合并症和多种药物治疗的患者。